Voyageur Pharmaceuticals CEO Brent Willis joins Proactive's Natalie Stoberman to share the latest results from its SmoothX comparative studies.
Willis says results of the double-blind testing showed that SmoothX was favoured on drinkability and taste by 75% of patients compared to the competing product.
Before SmoothX goes to market, Willis adds a medical white paper is currently in preparation that will provide an in-depth analysis of the studies and insights into the effectiveness of SmoothX to educate and inform doctors and medical staff about the product's benefits for abdominal CT diagnostic imaging procedures.
Proactive Investors
+1 604-688-8158
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.05 |
| Daily Volume: | 0 |
| Market Cap: | US$6.280M |
December 20, 2024 September 05, 2024 May 28, 2024 December 21, 2023 | |
DevvStream provides upfront capital for sustainability projects in exchange for carbon credit rights. Through these rights, the company generates and manages carbon credits by utilizing the most technologically advanced...
CLICK TO LEARN MORE
Leveraging its vertically-integrated approach from mine to material manufacturing, Graphite One intends to produce high-grade anode material for the lithium-ion electric vehicle battery market and energy storage systems...
CLICK TO LEARN MORE
